


Figure 1



Pioglitazone treatment and GLP-1 RAs: benefitting T2DM, NAFLD & CVD risk

Figure 2

(i) NAFLD: as a public health burden

(ii) Impacts on healthcare

(iii) Evidence (e.g. aetiology, diagnosis, treatment, consequences)

(iv) Guidelines

Non specialist
HCP awareness

Civil
awareness

(v) Lobbying groups

(vi) Strategy & Policy for NAFLD

PROBLEM

**RESEARCH,
ADVICE &
AWARENESS**

PRESSURE

**EFFECTING
CHANGE**